These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1071754)

  • 1. Antihypertensive treatment and plasma renin activity in essential hypertension.
    Chen WY; Hsieh BS; Yen TS; Cheng JT; Yang SM
    Taiwan Yi Xue Hui Za Zhi; 1976 Dec; 75(12):665-73. PubMed ID: 1071754
    [No Abstract]   [Full Text] [Related]  

  • 2. RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients.
    Semplicini A; Strapazzon G; Papparella I; Sartori M; Realdi A; Macchini L; Calò LA; Ceolotto G
    J Hypertens; 2010 May; 28(5):1104-8. PubMed ID: 20375904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [SP 54 therapy in hypertension. The effect of SP 54 on blood pressure, renin and aldosterone as well as electrolyte balance in patients with hypertension].
    Werning C; Stiel D; Hammann K; Schweikert HU; Fischer N; Siegenthaler W
    Fortschr Med; 1972 Jul; 90(20):785-7. PubMed ID: 5074231
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of antihypertensive treatment based on plasma renin activity: An open label observational study.
    Leotta G; Rabbia F; Testa E; Totaro S; Abram S; Milan A; Mulatero P; Veglio F
    Blood Press; 2010 Aug; 19(4):218-24. PubMed ID: 20367559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma renin activity and blood pressure response to antihypertensive agents. A proposal for management of essential and renal hypertension.
    Tanaka K; Fukiyama K; Kumamoto K; Yamamoto Y; Oniki H; Omae T
    Jpn Circ J; 1975 Jul; 39(7):805-10. PubMed ID: 1159940
    [No Abstract]   [Full Text] [Related]  

  • 6. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension.
    Minami J; Ohno E; Furukata S; Ishimitsu T; Matsuoka H
    J Hum Hypertens; 2009 Oct; 23(10):683-6. PubMed ID: 19369955
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antihypertensive effect of carteolol, a beta-receptor blockader, in essential hypertension and its action on the renin-aldosterone system].
    Hata S; Kunita H
    Horumon To Rinsho; 1977 Aug; 25(8):907-15. PubMed ID: 334398
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
    Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
    N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pindolol as an antihypertensive agent].
    Pinggera WF; Fitscha P; Stummvoll HK; Wolf A; Dorda P
    Fortschr Med; 1977 Feb; 95(5):310-14. PubMed ID: 838451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antihypertensive effects of coenzyme Q10 in essential hypertension--in relation to the renin-aldosterone system].
    Hata S; Kunida H; Oyama Y
    Horumon To Rinsho; 1977 Sep; 25(9):1019-23. PubMed ID: 923110
    [No Abstract]   [Full Text] [Related]  

  • 11. Physiologic mechanisms of bupicomide- and hydralazine-induced increase in plasma renin activity in hypertensive patients.
    Velasco M; McNay JL
    Mayo Clin Proc; 1977 Jul; 52(7):430-2. PubMed ID: 875465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
    Sim JJ; Bhandari SK; Shi J; Kalantar-Zadeh K; Rasgon SA; Sealey JE; Laragh JH
    Am J Hypertens; 2012 Mar; 25(3):379-88. PubMed ID: 22158065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients.
    Gavras H; Brunner HR; Laragh JH; Sealey JE; Gavras I; Vukovich RA
    N Engl J Med; 1974 Oct; 291(16):817-21. PubMed ID: 4371298
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pressor responses to antihypertensive drug types.
    Alderman MH; Cohen HW; Sealey JE; Laragh JH
    Am J Hypertens; 2010 Sep; 23(9):1031-7. PubMed ID: 20725055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the renin-angiotensin system in hypertension in the elderly.
    Nagano M; Higaki J; Mikami H; Ogihara T
    Blood Press Suppl; 1994; 5():130-3. PubMed ID: 7889195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.
    Sealey JE; Laragh JH
    Am J Hypertens; 2009 Jan; 22(1):112-21. PubMed ID: 18802434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin profiling to predict response to antihypertensive therapy.
    Blaufox MD; Wassertheil-Smoller S
    JAMA; 1999 Mar; 281(9):793-4. PubMed ID: 10070992
    [No Abstract]   [Full Text] [Related]  

  • 19. Renin reactivity as a determinant of responsiveness to antihypertensive treatment.
    Weber MA; Lopez-Ovejero JA; Drayer JI; Case DB; Laragh JH
    Arch Intern Med; 1977 Mar; 137(3):284-9. PubMed ID: 843146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measurement of plasma renin activity, blood volume and exchangeable sodium: an aid in the orientation of treatment of essential arterial hypertension].
    Olmer M; Ducros J; Grandvuillemin M; Salvadori JM
    Sem Hop; 1977 May; 53(20):1147-53. PubMed ID: 20666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.